Director/PDMR shareholdings in the Company
EDX Medical Group plc has announced changes in major shareholdings due to dilution from a recent equity fundraising. Dr. Michael Hudson, CEO, and his associates now hold 20,650,000 ordinary shares, representing 4.79% of the company's share capital. Professor Sir Christopher Evans, founder and chief scientific officer, continues to hold 136,220,293 ordinary shares, now representing 31.58% of the share capital, which includes an additional 58,770 shares acquired in 2025 and January 2026 due to an administrative oversight.
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops and supplies innovative digital diagnostic products and services for the early detection and treatment of major diseases, has received notification of the following reductions in shareholding as a result of the dilution from the recent equity fundraising.
Dr Michael Hudson, chief executive officer, and his persons closely associated, continues to hold a total of 20,650,000 ordinary shares which now represent 4.79% of the share capital of the Company.
Professor Sir Christopher Evans, founder and chief scientific officer, continues to hold 136,220,293 ordinary shares which now represent 31.58% of the share capital of the Company. This total includes an additional 58,770 ordinary shares compared to previous notifications as a result of purchases in 2025 and January 2026 that were made on his behalf but that were not notified at the time due to an administrative oversight.
The directors of the Company accept responsibility for the contents of this announcement.
TR-1: Standard form for notification of major holdings
- Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
- Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
| An event changing the breakdown of voting rights | X |
Other (please specify) iii :
Details of person subject to the notification obligation iv
| Name | Dr Michael Hudson |
City and country of registered office (if applicable)
Full name of shareholder(s) (if different from 3.) v
| Name | Hargreaves Lansdown (Nominees) Limited (indirect holdings only) |
| City and country of registered office (if applicable) | Bristol, United Kingdom |
| 5. Date on which the threshold was crossed or reached vi : | 28 August 2026 |
| 6. Date on which issuer notified (DD/MM/YYYY): | 1 September 2026 |
- Total positions of person(s) subject to the notification obligation
| Resulting situation on the date on which threshold was crossed or reached | 4.79 | 4.79 | 20,650,000 | |
| Position of previous notification (if applicable) | ||||
| A: Voting rights attached to shares | ||||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | ||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | |
| GB00BNDMJS47 | 20,000,000 | 650,000 | 4.64 | 0.15 |
| SUBTOTAL 8. A | 20,650,000 | 4.79 | ||
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
SUBTOTAL 8.B.2
In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
Additional information xvi
| Place of completion | London |
| Date of completion | 1 September 2026 |
Notes
Name of ultimate controlling person A (chain 1)
Name of controlled undertaking B
Name of controlled undertaking C
Name of ultimate controlling person A (chain 2)
Name of controlled undertaking B
Name of controlled undertaking D
Name of ultimate controlling person A (chain3)
Name of controlled undertaking E
Name of controlled undertaking F
xvi Example: Correction of a previous notification.
TR-1: Standard form for notification of major holdings
- Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
- Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
| An event changing the breakdown of voting rights | X |
Other (please specify) iii :
Details of person subject to the notification obligation iv
| Name | Professor Sir Christopher Evans |
City and country of registered office (if applicable)
Full name of shareholder(s) (if different from 3.) v
| Name | Platform Securities Nominees Limited (indirect holdings only) |
| City and country of registered office (if applicable) | London, United Kingdom |
| 5. Date on which the threshold was crossed or reached vi : | 28 August 2026 |
| 6. Date on which issuer notified (DD/MM/YYYY): | 1 September 2026 |
- Total positions of person(s) subject to the notification obligation
| Resulting situation on the date on which threshold was crossed or reached | 31.58 | 31.58 | 136,220,293 | |
| Position of previous notification (if applicable) | 33.08 | 33.08 | ||
| A: Voting rights attached to shares | ||||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | ||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | |
| GB00BNDMJS47 | 130,250,000 | 5,970,293 | 30.19 | 1.38 |
| SUBTOTAL 8. A | 136,220,293 | 31.58 | ||
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
SUBTOTAL 8.B.2
In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
Additional information xvi
| Place of completion | London |
| Date of completion | 1 September 2026 |
Notes
Name of ultimate controlling person A (chain 1)
Name of controlled undertaking B
Name of controlled undertaking C
Name of ultimate controlling person A (chain 2)
Name of controlled undertaking B
Name of controlled undertaking D
Name of ultimate controlling person A (chain3)
Name of controlled undertaking E
Name of controlled undertaking F
xvi Example: Correction of a previous notification.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Professor Sir Christopher Evans |
| 2 | Reason for the notification | |
| a) | Position/status | Board Director / Chief Scientific Officer |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | EDX Medical Group plc |
| b) | LEI | 213800BZVJZTMCZ6DJ63 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each |
| Identification code | ISIN: GB00BNDMJS47 | |
| b) | Nature of the transaction | Purchase of shares on market |
| c) | Price(s) and volume(s) | |
| Price | Volume | |
| £0.1240 £0.1200 £0.1329 | 20,000 20,000 18,770 | |
| d) | Aggregated information | |
| - Aggregated volume | 58,770 | |
| - Price | £0.1240; £0.1200; £0.1329 | |
| e) | Date of the transaction(s) | 2025-02-21; 2025-09-08; 2026-01-09 |
| f) | Place of the transaction(s) | AQSE- Aquis Growth Market (Equity) |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.